Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

People In The News – Tracking The Latest Industry Personnel Moves

  • News

Executive Summary

Presidents & CEOs

You may also be interested in...



Frank Baldino, Cephalon CEO, Chairman, And Founder Dies At 57

Cephalon's Founder, CEO and Chairman Frank Baldino Jr. died Thursday Dec. 16, nearly four months after taking a temporary medical leave of absence.

Pfizer Turns To Insider Ian Read To See It Into Post-Lipitor Era

The 32-year Pfizer veteran will take over for Jeffrey Kindler in a succession viewed as a surprise by Wall Street.

Big Pharma CEOs Suggest Policy Changes As They Return To Beijing

Global CEOs of J&J, Pfizer, AbbVie and Takeda were among the top pharma executives attending the China Development Forum in its first in-person meeting in three years, and highlighted a number of pharma-related policy changes they would like to see in China. Meanwhile, a Japanese employee of Astellas has been detained in the country for alleged espionage.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Shared Savings Legislation Could Increase Medicare Biosimilar Access

Positive Feelings About Negative Controls: US FDA Explores Another Tool For The Real-World Evidence Toolbox

Game On: Medicare Will Parry Manufacturer Efforts To Sidestep Price Negotiation, Guidance Says

US FDA Expands In-Person Meeting Eligibility, But So Far No Takers

See All
UsernamePublicRestriction

Register

PS052992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By